

Medicines & Healthcare products Regulatory Agency



# **MHRA Post Transition Update**

#### **Craig Copland**



#### **MHRA Post Brexit Update**

- MHRA Responsibilities under the Tobacco and Related Products Regulations 2016
- Product Notification Process
- Compliance Findings 2021
- Yellow Cards and ADR Reports
- Market Surveillance and Cross Agency Collaboration

#### **Post-Brexit regulatory environment**


- From Jan 1<sup>st</sup>, 2021, the MHRA has delivered a dedicated GB only submission portal – MHRA Submissions
- Provide continuity for existing products by retaining current ECIDs and submitter IDs

#### **GB** Notification Process

When is a product Notified ?

- Product submission successfully validated by MHRA Submissions
- Fee Paid
- Completion of successful manual assessment
- Published on MHRA website

### **GB** notification process



### **Compliance issues in notifications**


- Submission data missing mandatory requirements for system validation
- Fee payment unsuccessful
- Non- compliant Toxicology / Emissions / Ingredients
- Responsible Persons information incomplete
- Required corrective action incomplete

## **Compliance – Corrective Actions**

Increase in required corrective actions between 2020 and 2021:


- Automated validation is assisting targeted manual reviews
- Publication rates higher than 2020
- Increase in new submitters
   due to disposable products

#### **Corrective Actions**



Product Submissions
Requiring Corrective Action

#### Yellow Card – A Decade of Reporting



#### 150 Yellow Card reports received by the MHRA

Medicines & Healthcare products Regulatory Agency E-cigarettes and

Yellow Card

#### e-liquids need to meet quality standards

Report any issues to mhra.gov.uk/yellowcard

## **EVALI - MHRA response**

- Review of FDA Data
- Guidance for medical professionals Drug Safety Update
- CHM review of Data
- ADR reports requested from E-Cigarette Submitters for review (125)

#### **Yellow Card and Industry ADR Reports**

99 (36%) were reported by members of the public

51 (19%) were reported by healthcare professionals

125 (45%) were reported by industry

768 symptoms recorded across the 275 reports

#### **Market Surveillance Activities**

In 2021/22 the MHRA has received more than a 100% increase in intelligence referrals. These predominantly relate to:

- The notification status of products
- Provision of product notification data to support ongoing investigations
- Provision of evidence packages to support legal action
- Disposable Products

#### **Market Surveillance – Disposable Publications**



#### **Market Surveillance Activities**

In 2021/22 the MHRA has disseminated over 200 intelligence referrals to external agencies. A significant increase from 2020, 2019 and 2018. These predominantly relate to disposable products:

- Non compliant products notified for/or supplied to the UK market
- Takedown referrals via TS Primary Authority Partnerships

#### **Market Surveillance Activities - Partnership**

- Trading Standards Collaboration on projects assessing retail and supply compliance, increased data sharing between agencies, increased MHRA staffing to support enforcement referrals and related work in 2022.
- Regular updates to the CTSI Tobacco Focus Group
- Collaborative working group with Trading Standards, Health and Safety Executive, HMRC, OPSS and Ports and Borders to provide updates on E-cigarette issues